Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen Licenses JAK Inhibitor from Astellas | Contract Pharma

What are you searching for?

Sign in
Breaking News

Janssen Licenses JAK Inhibitor from Astellas

Gains rights to ASP015K for immune-mediated inflammatory diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Janssen Biotech and Astellas Pharma have entered into a license agreement for the worldwide development and commercialization (except in Japan) of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor currently in Phase II development as a treatment for moderate-to-severe rheumatoid arthritis (RA) and plaque psoriasis.
 
Janssen, a J&J subsidiary, gains exclusive worldwide rights to ASP015K for immune-mediated inflammatory diseases. Astellas will receive an undisclosed upfront payment and is eligible for future milestone and royalty payments. Astellas will be responsible for completing Phase II studies. Janssen will be responsible for all other development, clinical and regulatory filing activities in its territories. Astellas will continue development and commercialization of ASP015K in Japan.
 
“Janssen has a heritage of innovation and delivering transformative medicines to address unmet needs in immunologic diseases,” said Susan Dillon, Ph.D., global therapeutic area head, Immunology, Janssen R&D, LLC. “We are committed to expanding the portfolio of new treatments for patients with serious immune-mediated diseases and are excited to add Astellas’ ASP015K to our pipeline.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics